Taking Lessons From Hematology Experts in Tampa

By
Article

We headed to Tampa, Florida for a State of the Science Summit on Hematologic Malignancies. The meeting covered updates in follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic myeloid leukemia, acute myeloid leukemia, myeloproliferative neoplasms, and CAR T-cell therapy.

We headed to Tampa, Florida for a State of the Science Summit on Hematologic Malignancies. The meeting covered updates in follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic myeloid leukemia, acute myeloid leukemia, myeloproliferative neoplasms, and CAR T-cell therapy.

Recent Videos
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
William Chou, MD, on Targeting Progranulin With Gene Therapy for Frontotemporal Dementia
Alexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio
David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI
Joshua M. Hare, MD, on Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy
John Finn, PhD, the chief scientific officer of Tome Biosciences
David Dimmock, MBBS, on a Promising Case Study of Ultra-Rare, AI-Guided, ASO Development
William Chou, MD, on Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations
Scott Jeffers, PhD, on The Importance of Precise Reproducibility of AAVs
Related Content
CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – September 6, 2024

CGTLive Staff
September 6th 2024
Article

Review top news and interview highlights from the week ending September 6, 2024.

Miloš Miljković, MD, chief medical officer, Cartesian Therapeutics

mRNA-CAR-T Descartes-08's Potential for Treating Myasthenia Gravis

Miloš Miljković, MD;Noah Stansfield
September 6th 2024
Article

Miloš Miljković, MD, the chief medical officer of Cartesian Therapeutics, discussed data presented at ASGCT 2024 from a phase 2a study.

Cartesian Therapeutics Doses First Patient With mRNA CAR-T Descartes-15 in Trial for R/R Multiple Myeloma

Cartesian Therapeutics Doses First Patient With mRNA CAR-T Descartes-15 in Trial for R/R Multiple Myeloma

Noah Stansfield
September 6th 2024
Article

Pending the results of the trial, Cartesian plans to eventually evaluate Descartes-15 for the treatment of autoimmune diseases.

Biogen’s Nusinersen Shows Efficacy in SMA Compared With Sham Treatment at Experimental Higher Dose

Biogen’s Nusinersen Shows Efficacy in SMA Compared With Sham Treatment at Experimental Higher Dose

Noah Stansfield
September 5th 2024
Article

The data come from the pivotal part B cohort of the phase 2/3 DEVOTE clinical trial.

Ractigen Garners Orphan Drug Designation for Muscular Dystrophy saRNA Therapy RAG-18

Ractigen Garners Orphan Drug Designation for Muscular Dystrophy saRNA Therapy RAG-18

Noah Stansfield
September 5th 2024
Article

Notably, the therapy previously received rare pediatric disease designation from the FDA in July 2024.

Around the Helix: Cell and Gene Therapy Company Updates – September 4, 2024

Around the Helix: Cell and Gene Therapy Company Updates – September 4, 2024

Noah Stansfield
September 4th 2024
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

© 2024 MJH Life Sciences

All rights reserved.